SCRI Development Innovations, LLC: all 179 studies

Page 1 of 2. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.

• A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT07637578Phase 2
• A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)RecruitingNCT07011576Phase 2
• Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple MyelomaRecruitingNCT06974786Phase 2
• Outpatient Administration of Teclistamab or Talquetamab for Multiple MyelomaRecruitingNCT05972135Phase 2
• Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerRecruitingNCT05748834Phase 2
• A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast CancerCompletedNCT04699630Phase 2Results posted
• Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell LymphomaCompletedNCT04402138Phase 2Results posted
• A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid LeukemiaTerminatedNCT04209725Phase 2Results posted
• A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)TerminatedNCT04200365Phase 2Results posted
• Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 InhibitorCompletedNCT03977467Phase 2Results posted
• Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression RiskCompletedNCT03436862Phase 2Results posted
• Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial CarcinomaTerminatedNCT02887248Phase 2Results posted
• Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 MicrospheresTerminatedNCT02859064Phase 2Results posted
• Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma PatientsCompletedNCT02843074Phase 2Results posted
• Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic AlterationsCompletedNCT02795156Phase 2Results posted
• Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine CancersCompletedNCT02318784Phase 2Results posted
• Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal CancerCompletedNCT02317991Phase 2Results posted
• Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast CancerCompletedNCT02291913Phase 2Results posted
• Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple MyelomaTerminatedNCT02254551Phase 2Results posted
• Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver MetastasesCompletedNCT02195011Phase 2Results posted
• Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple MyelomaCompletedNCT02168101Phase 2Results posted
• Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) LymphomaTerminatedNCT02113007Phase 2Results posted
• Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)CompletedNCT01990209Phase 2Results posted
• Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial MetastasesTerminatedNCT01934894Phase 2Results posted
• Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic LeukemiaCompletedNCT01848145Phase 2Results posted
• Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic CancerCompletedNCT01844817Phase 2Results posted
• Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung CancerCompletedNCT01829113Phase 2Results posted
• Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric CancerTerminatedNCT01769508Phase 2Results posted
• 5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal CancerCompletedNCT01749956Phase 2Results posted
• Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP ChemotherapyCompletedNCT01626352Phase 2Results posted
• Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or StomachCompletedNCT01611857Phase 1/2Results posted
• Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast CancerCompletedNCT01527487Phase 2Results posted
• Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT01496118Phase 1/2Results posted
• A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)CompletedNCT01490866Phase 2Results posted
• Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to ErlotinibCompletedNCT01487265Phase 2Results posted
• Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal TumorCompletedNCT01404650Phase 2Results posted
• Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant ChemotherapyCompletedNCT01401959Phase 2Results posted
• Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma MultiformeCompletedNCT01349660Phase 1/2Results posted
• A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid TumorsCompletedNCT01226732Phase 1Results posted
• FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases OnlyCompletedNCT01226719Phase 2Results posted
• Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal CancerCompletedNCT01154335Phase 1Results posted
• Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine CancersCompletedNCT01121939Phase 2Results posted
• Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01113632Phase 2Results posted
• A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT01076504Phase 2Results posted
• Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose ChemotherapyCompletedNCT01056276Phase 2Results posted
• Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast CancerCompletedNCT01048099Not applicableResults posted
• Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLCCompletedNCT01042288Phase 2Results posted
• Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal AdenocarcinomaTerminatedNCT01035658Phase 1/2Results posted
• Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast CancerCompletedNCT01033032Phase 1/2Results posted
• Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade LymphomaCompletedNCT01029730Phase 2Results posted
• Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung CancerCompletedNCT01027598Phase 2Results posted
• Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic MelanomaCompletedNCT01014351Phase 2Results posted
• Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial MeningiomaTerminatedNCT00972335Phase 2Results posted
• Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLCTerminatedNCT00960297Phase 2Results posted
• Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast CancerCompletedNCT00915603Phase 2Results posted
• Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung CancerCompletedNCT00906282Phase 2Results posted
• Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast CancerCompletedNCT00894504Phase 2Results posted
• Trial of Poor Performance Status Patients (ToPPS)CompletedNCT00892710Phase 2Results posted
• Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast CancerCompletedNCT00887575Phase 1/2Results posted
• Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast CancerCompletedNCT00866905Phase 2Results posted
• Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the PancreasCompletedNCT00837031Phase 2Results posted
• Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast CancerCompletedNCT00825734Phase 1/2Results posted
• Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast CancerCompletedNCT00821886Phase 2Results posted
• RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBMCompletedNCT00805961Phase 2Results posted
• A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast CancerCompletedNCT00789581Phase 3Results posted
• Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung CancerCompletedNCT00741988Phase 2Results posted
• Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary SiteCompletedNCT00737243Phase 2Results posted
• Pazopanib in Previously Treated Patients With Metastatic Renal Cell CarcinomaCompletedNCT00731211Phase 2Results posted
• Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung CancerCompletedNCT00695292Phase 2Results posted
• Rituximab, Lenalidomide, and Bortezomib in Mantle Cell LymphomaCompletedNCT00633594Phase 1/2Results posted
• LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer PatientsCompletedNCT00632489Phase 1Results posted
• Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast CancerCompletedNCT00629499Phase 2Results posted
• Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLCCompletedNCT00621049Phase 2Results posted
• Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on ErlotinibCompletedNCT00609804Phase 2Results posted
• Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)CompletedNCT00600015Phase 2Results posted
• LBH589 in Refractory Myelodysplastic Syndromes (MDS)TerminatedNCT00594230Phase 2Results posted
• RAD001 Plus Bevacizumab in Metastatic MelanomaCompletedNCT00591734Phase 2Results posted
• LBH589 Treatment for Refractory Clear Cell Renal CarcinomaCompletedNCT00550277Phase 2Results posted
• Vinflunine in Hormone Refractory Prostate Cancer (HRPC)CompletedNCT00545766Phase 2Results posted
• Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma MultiformeCompletedNCT00544817Phase 2Results posted
• Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast CancerCompletedNCT00544167Not applicableResults posted
• CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the PancreasCompletedNCT00540579Phase 1/2Results posted
• Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma PatientsCompletedNCT00536575Phase 1/2Results posted
• Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)CompletedNCT00536341Phase 1/2Results posted
• First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLCCompletedNCT00456261Phase 2Results posted
• High-dose Bevacizumab in Advanced Renal Carcinoma PatientsCompletedNCT00455975Phase 2Results posted
• Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast CancerCompletedNCT00405938Phase 2Results posted
• Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung CancerTerminatedNCT00402883Phase 2Results posted
• Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal CancerCompletedNCT00393068Phase 2Results posted
• Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney CancerCompletedNCT00392821Phase 1/2Results posted
• Treatment of Head & Neck Cancer With Chemotherapy and RadiationCompletedNCT00392704Phase 2Results posted
• Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast CancerCompletedNCT00392392Phase 2Results posted
• Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian CancerCompletedNCT00390611Phase 2Results posted
• Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary SiteCompletedNCT00360360Phase 2Results posted
• Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal CarcinomaCompletedNCT00323739Phase 2Results posted
• 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal CancerCompletedNCT00308516Phase 2Results posted
• Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung CancerCompletedNCT00305942Phase 2Results posted
• Trastuzumab and Oxaliplatin in Patients With Metastatic Breast CancerCompletedNCT00297596Phase 2Results posted
• Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast CancerCompletedNCT00284180Phase 2Results posted
• Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung CancerCompletedNCT00284154Phase 2Results posted

← SCRI Development Innovations, LLC overview and focus areas